Physician profile
Seema Nanda
NPI 1568465813
$87,477.80
in general payments reported to CMS, 2019-2025
28 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $13K · 2021: $6,795 · 2022: $42K · 2023: $2,017 · 2024: $1,047 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,063 · Consulting Fee: $750 · Travel and Lodging: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,062.50 |
| Consulting Fee | $750.00 |
| Travel and Lodging | $332.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29,266.05 | 2019-2022 | |
| Biotissue Holdings INC. | $26,363.35 | 2019-2025 | |
| Abbvie INC. | $10,198.48 | 2022-2023 | |
| Quidel Corporation | $7,683.67 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $4,005.50 | 2020-2022 | |
| Tearlab Corp | $1,865.06 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,556.87 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $1,191.97 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $1,000.14 | 2023-2025 | Xiidra, Vyzulta, Miebo |
| Shire North American Group INC | $598.53 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $495.67 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $490.96 | 2025 | Cirrus Hd-Oct |
| Tarsus Pharmaceuticals, INC. | $425.05 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $380.96 | 2024-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $320.97 | 2021-2023 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $314.38 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $313.86 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $226.60 | 2019-2021 | |
| Alcon Vision LLC | $215.77 | 2024-2025 | Rocklatan, Tryptyr, Precision 1 |
| Rxsight INC | $127.18 | 2022 | |
| Mallinckrodt Enterprises LLC | $116.66 | 2019 | |
| Coopervision INC. | $110.00 | 2019 | |
| Derma Sciences, INC. | $56.39 | 2019 | |
| Sight Sciences, INC. | $46.39 | 2020 | |
| Haag-Streit USA, INC. | $35.66 | 2023 | |
| Eyevance Pharmaceuticals LLC | $33.29 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.99 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.